Low hemagglutinin antigen dose influenza vaccines adjuvanted with AS03 alter the long-term immune responses in BALB/c mice

References

• Statistics Canada (2010). Canadian Community Health Survey: H1N1 Vaccinations. Statistics Canada http://www.statcan.gc.ca/daily-quotidien/100719/dq100719b-eng.htm
   Google Scholar
• GlaxoSmithKline Inc (2009). Arepanrix H1N1 [package insert]. Mississauga, ON, Canada
   Google Scholar
• Leroux-Roels G. Prepandemic H5N1 influenza vaccine adjuvanted with AS03: a review of the pre-clinical and clinical data. Expert Opin Biol Ther 2009; 9:1057-71; PMID:19555313; http://dx.doi.org/10.1517/14712590903066695
   PubMed Web of Science ®Google Scholar
• Health Canada (2010). Product Information Leaflet Arepanrix™ H1N1 AS03-Adjuvanted H1N1 Pandemic Influenza Vaccine - Version 4 approved 20 April 2010. Health Canada http://www.hc-sc.gc.ca/dhp-mps/prodpharma/legislation/interimorders-arretesurgence/prodinfo-vaccin-eng.php
   Google Scholar
• Yam KK, Gupta J, Brewer A, Scheifele DW, Halperin S, Ward BJ. Unusual Patterns of IgG Avidity in Some Young Children following Two Doses of the Adjuvanted Pandemic H1N1 (2009) Influenza Virus Vaccine. Clin Vaccine Immunol 2013; 20:459-67; PMID:23345582; http://dx.doi.org/10.1128/CVI.00619-12
   PubMed Web of Science ®Google Scholar
• Yam KK, Gupta J, Winter K, Allen E, Brewer A, Beaulieu E, Mallett CP, Burt DS, Ward BJ. AS03-Adjuvanted, Very-Low-Dose Influenza Vaccines Induce Distinctive Immune Responses Compared to Unadjuvanted High-Dose Vaccines in BALB/c Mice. Front Immunol 2015; 6:207; PMID:25972874; http://dx.doi.org/10.3389/fimmu.2015.00207
   PubMed Web of Science ®Google Scholar
• Morel S, Didierlaurent A, Bourguignon P, Delhaye S, Baras B, Jacob V, Planty C, Elouahabi A, Harvengt P, Carlsen H et al. Adjuvant System AS03 containing alpha-tocopherol modulates innate immune response and leads to improved adaptive immunity. Vaccine 2011; 29:2461-73; PMID:21256188; http://dx.doi.org/10.1016/j.vaccine.2011.01.011
   PubMed Web of Science ®Google Scholar
• Coffman RL, Sher A, Seder RA. Vaccine adjuvants: putting innate immunity to work. Immunity 2010; 33:492-503; PMID:21029960; http://dx.doi.org/10.1016/j.immuni.2010.10.002
   PubMed Web of Science ®Google Scholar
• Bromage E, Stephens R, Hassoun L. The third dimension of ELISPOTs: quantifying antibody secretion from individual plasma cells. J Immunol Methods 2009; 346:75-9; PMID:19465022; http://dx.doi.org/10.1016/j.jim.2009.05.005
   PubMed Web of Science ®Google Scholar
• Baz M, Samant M, Zekki H, Tribout-Jover P, Plante M, Lanteigne AM, Hamelin ME, Mallett C, Papadopoulou B, Boivin G. Effects of different adjuvants in the context of intramuscular and intranasal routes on humoral and cellular immune responses induced by detergent-split A/H3N2 influenza vaccines in mice. Clin Vaccine Immunol 2012; 19:209-18; PMID:22190392; http://dx.doi.org/10.1128/CVI.05441-11
   PubMed Web of Science ®Google Scholar
• Ann J, Samant M, Rheaume C, Dumas C, Beaulieu E, Morasse A, Mallett C, Hamelin ME, Papadopoulou B, Boivin G. Adjuvanted inactivated influenza A(H3N2) vaccines induce stronger immunogenicity in mice and confer higher protection in ferrets than unadjuvanted inactivated vaccines. Vaccine 2014; 32:5730-9; PMID:25173481; http://dx.doi.org/10.1016/j.vaccine.2014.08.029
   PubMed Web of Science ®Google Scholar
• Mallett CP, Beaulieu E, Joly MH, Baras B, Lu X, Liu F, Levine MZ, Katz JM, Innis BL, Giannini SL. AS03-adjuvanted H7N1 detergent-split virion vaccine is highly immunogenic in unprimed mice and induces cross-reactive antibodies to emerged H7N9 and additional H7 subtypes. Vaccine 2015; 33:3784-7; PMID:26100923; http://dx.doi.org/10.1016/j.vaccine.2015.06.053
   PubMed Web of Science ®Google Scholar
• Poder A, Simurka P, Li P, Roy-Ghanta S, Vaughn D. An observer-blind, randomized, multi-center trial assessing long-term safety and immunogenicity of AS03-adjuvanted or unadjuvanted H1N1/2009 influenza vaccines in children 10–17 years of age. Vaccine 2014; 32:1121-9; PMID:24252703; http://dx.doi.org/10.1016/j.vaccine.2013.11.031
   PubMed Web of Science ®Google Scholar
• Nolan T, Izurieta P, Lee BW, Chan PC, Marshall H, Booy R, Drame M, Vaughn DW. Heterologous prime-boost vaccination using an AS03B-adjuvanted influenza A(H5N1) vaccine in infants and children. J Infect Dis 2014; 210:1800-10; PMID:24973461; http://dx.doi.org/10.1093/infdis/jiu359
   PubMed Web of Science ®Google Scholar
• Langley JM, Reich D, Aggarwal N, Connor D, Lebel MH, Gupta A, Garfield H, Li P, Madan A, Vaughn DW. Randomized, multicenter trial of a single dose of AS03-adjuvanted or unadjuvanted H1N1 2009 pandemic influenza vaccine in children 6 months to. Pediatr Infect Dis J 2012; 31:848-58; PMID:22801094; http://dx.doi.org/10.1097/INF.0b013e31825e6cd6
   PubMed Web of Science ®Google Scholar
• Saitoh A, Nagai A, Tenjinbaru K, Li P, Vaughn DW, Roman F, Kato T. Safety and persistence of immunological response 6 months after intramuscular vaccination with an AS03-adjuvanted H1N1 2009 influenza vaccine: an open-label, randomized trial in Japanese children aged 6 months to 17 years. Hum Vaccin Immunother 2012; 8:749-58; PMID:22495117; http://dx.doi.org/10.4161/hv.19684
   PubMed Web of Science ®Google Scholar
• Gilca V, De SG, Hamelin ME, Boivin G, Ouakki M, Boulianne N, Sauvageau C, Dionne M, Gilca R, Skowronski D. Antibody persistence and response to 2010–2011 trivalent influenza vaccine one year after a single dose of 2009 AS03-adjuvanted pandemic H1N1 vaccine in children. Vaccine 2011; 30:35-41; PMID:22063386; http://dx.doi.org/10.1016/j.vaccine.2011.10.062
   PubMed Web of Science ®Google Scholar
• Yang WH, Dionne M, Kyle M, Aggarwal N, Li P, Madariaga M, Godeaux O, Vaughn DW. Long-term immunogenicity of an AS03-adjuvanted influenza A(H1N1)pdm09 vaccine in young and elderly adults: an observer-blind, randomized trial. Vaccine 2013; 31:4389-97; PMID:23856331; http://dx.doi.org/10.1016/j.vaccine.2013.07.007
   PubMed Web of Science ®Google Scholar
• Ikematsu H, Nagai H, Kawashima M, Kawakami Y, Tenjinbaru K, Li P, Walravens K, Gillard P, Roman F. Characterization and long-term persistence of immune response following two doses of an AS03A-adjuvanted H1N1 influenza vaccine in healthy Japanese adults. Hum Vaccin Immunother 2012; 8:260-6; PMID:22426369; http://dx.doi.org/10.4161/hv.18469
   PubMed Web of Science ®Google Scholar
• Yang PC, Yu CJ, Chang SC, Hsieh SM, Drame M, Walravens K, Roman F, Gillard P. Safety and immunogenicity of a split-virion AS03A-adjuvanted A/Indonesia/05/2005 (H5N1) vaccine in Taiwanese adults. J Formos Med Assoc 2012; 111:333-9; PMID:22748624; http://dx.doi.org/10.1016/j.jfma.2011.02.006
   PubMed Web of Science ®Google Scholar
• Langley JM, Risi G, Caldwell M, Gilderman L, Berwald B, Fogarty C, Poling T, Riff D, Baron M, Frenette L et al. Dose-sparing H5N1 A/Indonesia/05/2005 pre-pandemic influenza vaccine in adults and elderly adults: a phase III, placebo-controlled, randomized study. J Infect Dis 2011; 203:1729-38; PMID:21606531; http://dx.doi.org/10.1093/infdis/jir172
   PubMed Web of Science ®Google Scholar
• Leroux-Roels I, Roman F, Forgus S, Maes C, De BF, Drame M, Gillard P, van der Most R, Van MM, Hanon E et al. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study. Vaccine 2010; 28:849-57; PMID:19835828; http://dx.doi.org/10.1016/j.vaccine.2009.10.017
   PubMed Web of Science ®Google Scholar
• Risi G, Frenette L, Langley JM, Li P, Riff D, Sheldon E, Vaughn DW, Fries L. Immunological priming induced by a two-dose series of H5N1 influenza antigen, administered alone or in combination with two different formulations of AS03 adjuvant in adults: Results of a randomised single heterologous booster dose study at 15 months. Vaccine 2013; 31:436-7; PMID:23387064; http://dx.doi.org/10.1016/j.vaccine.2012.11.002
   PubMed Web of Science ®Google Scholar
• Ferguson M, Risi G, Davis M, Sheldon E, Baron M, Li P, Madariaga M, Fries L, Godeaux O, Vaughn D. Safety and long-term humoral immune response in adults after vaccination with an H1N1 2009 pandemic influenza vaccine with or without AS03 adjuvant. J Infect Dis 2012; 205:733-44; PMID:22315336; http://dx.doi.org/10.1093/infdis/jir641
   PubMed Web of Science ®Google Scholar
• Ikematsu H, Tenjinbaru K, Li P, Madan A, Vaughn D. Evaluation of immune response following one dose of an AS03A-adjuvanted H1N1 2009 pandemic influenza vaccine in Japanese adults 65 years of age or older. Hum Vaccin Immunother 2012; 8:1119-25; PMID:22854661; http://dx.doi.org/10.4161/hv.21081
   PubMed Web of Science ®Google Scholar
• Nicholson KG, Abrams KR, Batham S, Clark TW, Hoschler K, Lim WS, Medina MJ, Nguyen-Van-Tam JS, Read RC, Warren FC et al. Immunogenicity and safety of a two-dose schedule of whole-virion and AS03A-adjuvanted 2009 influenza A (H1N1) vaccines: a randomised, multicentre, age-stratified, head-to-head trial. Lancet Infect Dis 2011; 11:91-101; PMID:21168369; http://dx.doi.org/10.1016/S1473-3099(10)70296-6
   PubMed Web of Science ®Google Scholar
• Moris P, van der Most R, Leroux-Roels I, Clement F, Drame M, Hanon E, Leroux-Roels GG, Van MM. H5N1 influenza vaccine formulated with AS03A induces strong cross-reactive and polyfunctional CD4 T-cell responses. J Clin Immunol 2011; 31:443-54; PMID:21174144; http://dx.doi.org/10.1007/s10875-010-9490-6
   PubMed Web of Science ®Google Scholar
• Gillard P, Caplanusi A, Knuf M, Roman F, Walravens K, Moris P, Drame M, Schwarz TF. An assessment of prime-boost vaccination schedules with AS03A -adjuvanted prepandemic H5N1 vaccines: a randomized study in European adults. Influenza Other Respir Viruses 2013; 7:55-65; PMID:22405557; http://dx.doi.org/10.1111/j.1750-2659.2012.00349.x
   PubMed Web of Science ®Google Scholar
• Van Damme P, Kafeja F, Bambure V, Hanon E, Moris P, Roman F, Gillard P. Long-term persistence of humoral and cellular immune responses induced by an AS03A-adjuvanted H1N1 2009 influenza vaccine: an open-label, randomized study in adults aged 18–60 years and older. Hum Vaccin Immunother 2013; 9:1512-22; PMID:23571166; http://dx.doi.org/10.4161/hv.24504
   PubMed Web of Science ®Google Scholar
• Bergen MJ, Pan CH, Greer CE, Legg HS, Polo JM, Griffin DE. Comparison of the immune responses induced by chimeric alphavirus-vectored and formalin-inactivated alum-precipitated measles vaccines in mice. PLoS One 2010; 5:e10297; PMID:20421972; http://dx.doi.org/10.1371/journal.pone.0010297
   PubMedGoogle Scholar
• Taillardet M, Haffar G, Mondiere P, Asensio MJ, Gheit H, Burdin N, Defrance T, Genestier L. The thymus-independent immunity conferred by a pneumococcal polysaccharide is mediated by long-lived plasma cells. Blood 2009; 114:4432-40; PMID:19767510; http://dx.doi.org/10.1182/blood-2009-01-200014
   PubMed Web of Science ®Google Scholar
• Kim JH, Talbot HK, Mishina M, Zhu Y, Chen J, Cao W, Reber AJ, Griffin MR, Shay DK, Spencer SM et al. High-dose influenza vaccine favors acute plasmablast responses rather than long-term cellular responses. Vaccine 2016; 34:4594-601; PMID:27473306; http://dx.doi.org/10.1016/j.vaccine.2016.07.018
   PubMed Web of Science ®Google Scholar
• Henn AD, Rebhahn J, Brown MA, Murphy AJ, Coca MN, Hyrien O, Pellegrin T, Mosmann T, Zand MS. Modulation of single-cell IgG secretion frequency and rates in human memory B cells by CpG DNA, CD40L, IL-21, and cell division. J Immunol 2009; 183:3177-87; PMID:19675172; http://dx.doi.org/10.4049/jimmunol.0804233
   PubMed Web of Science ®Google Scholar
• Amsen D, Backer RA, Helbig C. Decisions on the road to memory. Adv Exp Med Biol 2013; 785:107-20; PMID:23456843; http://dx.doi.org/10.1007/978-1-4614-6217-0_12
   PubMed Web of Science ®Google Scholar
• Alter G, Sekaly RP. Beyond adjuvants: Antagonizing inflammation to enhance vaccine immunity. Vaccine 2015; 33 Suppl 2:B55-9; PMID:26022570; http://dx.doi.org/10.1016/j.vaccine.2015.03.058
   PubMedGoogle Scholar
• Yam KK, Gupta J, Allen EK, Burt KR, Beaulieu E, Mallett CP, Burt DS, Ward BJ. Comparison of AS03 and Alum on immune responses elicited by A/H3N2 split influenza vaccine in young, mature and aged BALB/c mice. Vaccine 2016; 34:1444-51; PMID:26873056; http://dx.doi.org/10.1016/j.vaccine.2016.02.012
   PubMed Web of Science ®Google Scholar
• Morel S, Denoel P, Godfroid F, Cortvrindt C, Vanderheyde N, Poolman J. Induction of Bordetella pertussis-specific immune memory by DTPa vaccines. Vaccine 2011; 29:3449-55; PMID:21382483; http://dx.doi.org/10.1016/j.vaccine.2011.02.062
   PubMed Web of Science ®Google Scholar
• Giannini SL, Hanon E, Moris P, Van MM, Morel S, Dessy F, Fourneau MA, Colau B, Suzich J, Losonksy G et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 2006; 24:5937-49; PMID:16828940; http://dx.doi.org/10.1016/j.vaccine.2006.06.005
   PubMed Web of Science ®Google Scholar
• Bernasconi NL, Traggiai E, Lanzavecchia A. Maintenance of serological memory by polyclonal activation of human memory B cells. Science 2002; 298:2199-202; PMID:12481138; http://dx.doi.org/10.1126/science.1076071
   PubMed Web of Science ®Google Scholar